drugset / Trial / NCT04176198
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Timeline
- Start
- 2019-12-16
- Primary completion
- 2027-04-30
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NUVISERTIB | Small molecule | — | Oral |
| Background | Momelotinib | Small molecule | — | Oral |
| Background | Ruxolitinib | Small molecule | — | Oral |